NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 4 - Central nervous system 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing
04.08.01 Control of epilepsy
MHRA: Antiepileptic drugs: new advice on switching between different manufacturers’ products for a particular drug NICE NG217: Epilepsy RCGP Top Tips for Dependence Forming Medication (2019)

Brivaracetam (Briviact®)
(Oral)

Amber SPA
Restricted Drug Restricted
10mg,25mg,50mg,75mg,100mg film-coated tablets
10mg/mL oral solution
Restricted to patients who cannot have levetiracetam.
BNF BNFc SPC

Cannabidiol (Epidyolex®)
(100 mg/ml oral solution)

RED
Restricted Drug Restricted

No GP Prescribing

For use in accordance with the following NICE TAs only

BNF BNFc SPC
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex

Cenobamate ( Ontozry®)
(12.5 mg tablets, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg film coated tablets)

Amber SPIS
Restricted Drug Restricted

To be used in accordance with NICE TA 753 

Entry reviewed June 2025

BNF BNFc SPC
NICE TA 753 Cenobamate for treating focal onset seizures in epilepsy

Felbamate

Amber SPIS
Formulary

unlicensed unlicensed

BNF BNFc SPC

Piracetam (Nootropil®)

Amber SPA
Formulary

Unlicensed Drug Unicensed use. 

800mg, 1200mg tablets.

Entry reviewed March 2025

BNF BNFc SPC

Stiripentol (Diacomit ®)

Amber SPIS
Formulary

250mg, 500mg capsules

250 mg, 500mg oral powder sachet

Entry reviewed March 2025

BNF BNFc SPC

Fenfluramine (Fintepla® )
(2.2mg/ml oral solution)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Fenfluramine is recommended as an add‑on to other anti-seizure medicines for treating seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in people aged 2 years and older in accordance with the following NICE TAs:

Funded by specialised commissioning

Entry reviewed March 2025

BNF BNFc SPC BlueTeq
NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome NICE TA1050: Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
04.08.01 Partial seizures with or without secondary generalisation
04.08.01 Carbamazepine and Oxcarbazepine
04.08.01 Ethosuximide
04.08.01 Gabapentin and pregabalin
04.08.01 Lacosamide
04.08.01 Lamotrigine
04.08.01 Levetiracetam
04.08.01 Perampanel
04.08.01 Phenobarbital and other barbiturates
04.08.01 Phenytoin
04.08.01 Rufinamide
04.08.01 Tiagabine
04.08.01 Topiramate
04.08.01 Valproate
04.08.01 Vigabatrin
04.08.01 Zonisamide
04.08.01 Benzodiazepines
04.08.01 Other Drugs
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.